Abstract
The use of stem cells to repair and replace damaged skeletal muscle cells in chronic, debilitating muscle diseases such as the muscular dystrophies holds great promise. Different stem cell populations, both of embryonic and adult origin display the potential to generate skeletal muscle cells and have been studied in animal models of muscular dystrophy. These include muscle derived satellite cells; bone marrow derived mesenchymal stem cells, muscle or bone marrow side population cells, circulating CD133+ cells and cells derived from blood vessel walls such as mesoangioblasts or pericytes. The design of effective stem cell based therapies requires a detailed understanding of the molecules and signaling pathways which determine myogenic lineage commitment and differentiation. We discuss the great strides that have been made in delineating these pathways and how a better understanding of muscle stem cell biology has the potential to lead to more effective stem cell based therapies for skeletal muscle regeneration for devastating muscle diseases.
Keywords: Skeletal Muscle Diseases, stem cells, muscular dystrophies, mesenchymal stem cells, mesoangioblasts, myogenesis
Current Stem Cell Research & Therapy
Title: Stem Cell Based Therapy for Skeletal Muscle Diseases
Volume: 3 Issue: 3
Author(s): Satyakam Bhagavati
Affiliation:
Keywords: Skeletal Muscle Diseases, stem cells, muscular dystrophies, mesenchymal stem cells, mesoangioblasts, myogenesis
Abstract: The use of stem cells to repair and replace damaged skeletal muscle cells in chronic, debilitating muscle diseases such as the muscular dystrophies holds great promise. Different stem cell populations, both of embryonic and adult origin display the potential to generate skeletal muscle cells and have been studied in animal models of muscular dystrophy. These include muscle derived satellite cells; bone marrow derived mesenchymal stem cells, muscle or bone marrow side population cells, circulating CD133+ cells and cells derived from blood vessel walls such as mesoangioblasts or pericytes. The design of effective stem cell based therapies requires a detailed understanding of the molecules and signaling pathways which determine myogenic lineage commitment and differentiation. We discuss the great strides that have been made in delineating these pathways and how a better understanding of muscle stem cell biology has the potential to lead to more effective stem cell based therapies for skeletal muscle regeneration for devastating muscle diseases.
Export Options
About this article
Cite this article as:
Bhagavati Satyakam, Stem Cell Based Therapy for Skeletal Muscle Diseases, Current Stem Cell Research & Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157488808785740343
DOI https://dx.doi.org/10.2174/157488808785740343 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds
Current Drug Delivery CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia
Current Cancer Drug Targets Human Carbonyl Reductases
Current Drug Metabolism Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Pretargeted Radioimmunotherapy with α-Particle Emitting Radionuclides
Current Radiopharmaceuticals ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma
Current Cancer Drug Targets Stem Cells in Kidney Transplantation: A Review of Chimerism-Based Protocols to Induce Transplantation Tolerance
Current Regenerative Medicine (Discontinued) HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy
Cardiovascular & Hematological Disorders-Drug Targets Autologus Stem Cell Transplatation as a Care Option in Elderly Patients. A Review
Anti-Cancer Agents in Medicinal Chemistry An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Thromboembolism with Immunomodulatory Agents in the Treatment of Multiple Myeloma
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug-Induced Hypokalaemia
Current Drug Safety Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design